Custom Feeds:
| All Blog Pages |
Category Feeds:
| Press releases |
-
Featured content
It’s Time for Commonsense Drug Pricing Solutions
A cheer went up among Vizient and our members last year when HHS announced the termination of the FDA’s Unapproved Drugs Initiative to curb rising drug costs. Our analysis found that ending the program could protect the U.S. health care system from an additional $7.52 billion of cost. Read why Vizient is advocating for commonsense drug pricing solutions as the Biden Administration and federal regulatory agencies may soon take up the issue.